Suffering

Global Pharmaceutical Treatments for Mental Health Disorders Market (2020 to 2025) - Conditions are Likely to Rise in the Near Future Due to the Consequences of COVID-19 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 24, 2021
Pharmaceutical, Health, Mental health, Psychiatry, Medical specialties, Health, Psychiatric diagnosis, Abnormal psychology, Mental disorder, Psychiatric assessment, Psychopathology, Suffering, Cognitive behavioral therapy, Social distancing, Obsessive–compulsive disorder

Evaluation of current market trends, market size, market forecast, pipeline analysis of new products, and regulatory scenarios and detailed analysis of drivers, challenges, and opportunities affecting market growth

Key Points: 
  • Evaluation of current market trends, market size, market forecast, pipeline analysis of new products, and regulatory scenarios and detailed analysis of drivers, challenges, and opportunities affecting market growth
    Description of biological factors such as anatomical, chemical and genetic traits, and psychological reasons such as conflict or trauma on the mental health and discussion on effect of COVID-19 pandemic, social distancing and social isolation on the mental health conditions
    A look at the markets for treatment of psychiatric disorders such as depression, anxiety and obsessive-compulsive disorder (OCD) and their co relation with COVID-19
    Details of technological advances and improvement in the development of pharmacological treatments, digital therapeutics (DTx) and cognitive behavioural therapy (CBT)
    Information on tele mental health software such as ReSet, Pears Somryst and Alkili's EndeavorRx which offers personalized treatment strategies and behavioural healthcare platform which plays an important role in the management of mental health disorders
    Snapshot of leading mental health conditions, and products in phase III development for selected psychiatric disorders
    Analysis of recent product developments including pharmacological and digital therapeutics, late-stage pipeline products and points of differentiation from existing therapies
    Market research suggests that mental health conditions are likely to rise in the near future due to the consequences of COVID-19 pandemic, social distancing and social isolation.

Life Clips to Acquire Mental Health Voice-Based AI Technology Company

Retrieved on: 
Wednesday, February 24, 2021
Psychiatry, Psychiatric diagnosis, Mind, Psychology, Abnormal psychology, Mental disorder, Psychiatric assessment, Psychopathology, Suffering, Mental health, Cognitive behavioral therapy, Psychiatry, Psychiatric diagnosis, Mind, Psychology, Abnormal psychology, Mental disorder, Psychiatric assessment, Psychopathology, Suffering, Mental health, Cognitive behavioral therapy

Dr. Manideep Gopishetty, CEO and Co-founder of Cognitive Apps, said, "Our advanced voice recognition AI technology diagnostic core can identify various mental health disorders.

Key Points: 
  • Dr. Manideep Gopishetty, CEO and Co-founder of Cognitive Apps, said, "Our advanced voice recognition AI technology diagnostic core can identify various mental health disorders.
  • With the acquisition, Life Clips gains access to Cognitive Apps' intellectual property, including AI enabled speech-based technology, and its research and development team.
  • Life Clips will further develop Cognitive Apps' technology for use in the development and testing of psychedelics for the treatment of various mental health disorders.
  • "Our mission is to make Life Clips a digital medicine company capable of disrupting the way data is captured and measured for various mental health disorders in modern healthcare.

National Spine and Pain Centers Names Douglas Badertscher President

Retrieved on: 
Tuesday, February 23, 2021
Nervous system, Branches of biology, Symptoms and signs, Acute pain, Nociception, Pain, Suffering

ROCKVILLE, Md., Feb. 23, 2021 /PRNewswire/ --National Spine and Pain Centers (NSPC), the nation's leading network of interventional pain practices, announced today that Douglas P. Badertscher has joined its leadership team as administrative President.

Key Points: 
  • ROCKVILLE, Md., Feb. 23, 2021 /PRNewswire/ --National Spine and Pain Centers (NSPC), the nation's leading network of interventional pain practices, announced today that Douglas P. Badertscher has joined its leadership team as administrative President.
  • Most recently, Badertscher served as President and COO of Pain Specialists of America.
  • About National Spine and Pain Centers:
    For more than 30 years, NSPC affiliated physicians have been pioneers in the relief of chronic and acute pain through minimally invasive procedures and leading-edge clinical research.
  • Medical services provided by independently operated physician practices branded as National Spine and Pain Centers and other affiliated brands.

PureHA Puts the Brakes on the Aging Process

Retrieved on: 
Monday, February 22, 2021
Nervous system, Branches of biology, Articles, Skin care, Nociception, Acute pain, Pain, Suffering, Cosmetics, Wellness, Health

FORT LAUDERDALE, Fla., Feb. 22, 2021 /PRNewswire/ --The aging process comes with a variety of side effects.

Key Points: 
  • FORT LAUDERDALE, Fla., Feb. 22, 2021 /PRNewswire/ --The aging process comes with a variety of side effects.
  • That's why Canadian health and wellness brand Revelox had everything from cosmetics to pain-relief in mind when they created PureHA.
  • PureHA addresses external aging concerns by rejuvenating skin and helping to promote the overall health of the body's largest organ.
  • PureHA has received positive reviews, with one even claiming that significant herniated pain was completely relieved "after only a week of taking PureHA."

2021 Pipeline Insights on the Postoperative Pain Industry - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 17, 2021
Pharmaceutical, Health, Surgery, Nervous system, Branches of biology, Symptoms and signs, Nociception, Acute pain, Suffering, Pain

This report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Postoperative pain pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Postoperative pain pipeline landscape.
  • "Postoperative pain - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication.
  • A detailed picture of the Postoperative pain pipeline landscape is provided which includes the disease overview and Postoperative pain treatment guidelines.
  • Postoperative pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Rise In Consumer Acceptance of Psychedelic Drug Therapies Is Quickly Increasing

Retrieved on: 
Wednesday, February 17, 2021
Psychoactive drugs, Branches of biology, Mind, Abnormal psychology, Mental disorder, Psychiatric assessment, Psychiatric diagnosis, Psychopathology, Suffering, Psychiatry, MDMA

Dr. Engle is Board Certified in Psychiatry and Neurology, with a clinical practice that combines functional medicine, integrative psychiatry, neuro-cognitive restoration.

Key Points: 
  • Dr. Engle is Board Certified in Psychiatry and Neurology, with a clinical practice that combines functional medicine, integrative psychiatry, neuro-cognitive restoration.
  • Traumatic brain injuries are a major cause of death and disability in North America and are increasing in number.
  • As part of this partnership, MindMed and MindShift Compounds AG have agreed to develop next-gen psychedelic and empathogenic substances together.
  • Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

Rise In Consumer Acceptance of Psychedelic Drug Therapies Is Quickly Increasing

Retrieved on: 
Wednesday, February 17, 2021
Psychoactive drugs, Branches of biology, Mind, Abnormal psychology, Mental disorder, Psychiatric assessment, Psychiatric diagnosis, Psychopathology, Suffering, Psychiatry, MDMA

Dr. Engle is Board Certified in Psychiatry and Neurology, with a clinical practice that combines functional medicine, integrative psychiatry, neuro-cognitive restoration.

Key Points: 
  • Dr. Engle is Board Certified in Psychiatry and Neurology, with a clinical practice that combines functional medicine, integrative psychiatry, neuro-cognitive restoration.
  • Traumatic brain injuries are a major cause of death and disability in North America and are increasing in number.
  • As part of this partnership, MindMed and MindShift Compounds AG have agreed to develop next-gen psychedelic and empathogenic substances together.
  • Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

 Cybin Inc. Releases Financial Highlights and Provides Business Update

Retrieved on: 
Wednesday, February 17, 2021
Biotechnology, Alternative medicine, Other Health, Health, Pharmaceutical, Psychiatry, Psychiatric assessment, Psychiatric diagnosis, Psychopathology, Psychology, Abnormal psychology, Mental disorder, Suffering, Mind

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

Key Points: 
  • Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
  • Although the management of Cybin believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect.
  • Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials.
  • If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybins performance and operations.

Holmusk Announces New Publication: Deep Learning-Based Natural Language Processing Models that Translate Unstructured Psychiatry Notes into Quantifiable Measures

Retrieved on: 
Tuesday, February 16, 2021
Branches of biology, Psychiatry, Mind, Abnormal psychology, Psychiatric diagnosis, Mental health, Mental disorder, Psychiatric assessment, Suffering, Disease

With this publication, Holmusk has validated its unique library of proprietary Natural Language Processing (NLP) models that translate unstructured psychiatry notes into quantifiable indicators of patient statuses (e.g., symptoms, side effects, and external stressors).

Key Points: 
  • With this publication, Holmusk has validated its unique library of proprietary Natural Language Processing (NLP) models that translate unstructured psychiatry notes into quantifiable indicators of patient statuses (e.g., symptoms, side effects, and external stressors).
  • By establishing these quantifiable indicators, Holmusk's models generate robust Real-World Evidence of disease progression and treatment efficacies for psychiatric disorders for the first time.
  • Holmusk will use the objective measures from these models to support measurement-based care and personalize care delivery in behavioral health across health systems.
  • The models convert 20+ years of electronic health record notes from Holmusk's MindLinc Global Database into over 240 psychiatrically relevant dimensions.

Holmusk Announces New Publication: Deep Learning-Based Natural Language Processing Models that Translate Unstructured Psychiatry Notes into Quantifiable Measures

Retrieved on: 
Tuesday, February 16, 2021
Branches of biology, Psychiatry, Mind, Abnormal psychology, Psychiatric diagnosis, Mental health, Mental disorder, Psychiatric assessment, Suffering, Disease

With this publication, Holmusk has validated its unique library of proprietary Natural Language Processing (NLP) models that translate unstructured psychiatry notes into quantifiable indicators of patient statuses (e.g., symptoms, side effects, and external stressors).

Key Points: 
  • With this publication, Holmusk has validated its unique library of proprietary Natural Language Processing (NLP) models that translate unstructured psychiatry notes into quantifiable indicators of patient statuses (e.g., symptoms, side effects, and external stressors).
  • By establishing these quantifiable indicators, Holmusk's models generate robust Real-World Evidence of disease progression and treatment efficacies for psychiatric disorders for the first time.
  • Holmusk will use the objective measures from these models to support measurement-based care and personalize care delivery in behavioral health across health systems.
  • The models convert 20+ years of electronic health record notes from Holmusk's MindLinc Global Database into over 240 psychiatrically relevant dimensions.